Skip to main content

HCW Biologics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

HCWB$0.95-6.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

HCW Biologics Inc.
Date: April 1, 2024By:/s/ Hing C. Wong, Ph.D.
Hing C. Wong, Ph.D.
Founder and Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Hing C. Wong and Rebecca Byam, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Hing C. Wong, Ph.D.Founder, Chief Executive OfficerApril 1, 2024
Hing C. Wong, Ph.D.(Principal Executive Officer)
/s/ Rebecca ByamChief Financial OfficerApril 1, 2024
Rebecca Byam(Principal Financial and Accounting Officer)
/s/ Scott T. GarrettChairperson of the Board of DirectorsApril 1, 2024
Scott T. Garrett
/s/ Lisa M. GilesDirectorApril 1, 2024
Lisa M. Giles
/s/ Rick S. GreeneDirectorApril 1, 2024
Rick S. Greene
/s/ Gary M. WinerDirectorApril 1, 2024
Gary M. Winer
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.